作者
Patricia A Assis, Lorena L De Figueiredo-Pontes, Ana Silvia G Lima, Vitor Leão, Larissa A Cândido, Carolina T Pintão, Aglair B Garcia, Fabiano P Saggioro, Rodrigo A Panepucci, Fernando Chahud, Arnon Nagler, Roberto P Falcão, Eduardo M Rego
发表日期
2015/12
期刊
Journal of Experimental & Clinical Cancer Research
卷号
34
页码范围
1-11
出版商
BioMed Central
简介
Background
Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-β (TGF-β) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models. Based on the fact that high levels of Vascular Endothelial Growth Factor (VEGF) and increased angiogenesis have been described in acute myeloid leukemia and associated with disease progression, we studied the in vivo effects of HF using an Acute Promyelocytic Leukemia (APL) mouse model.
Methods
NOD/SCID mice were transplanted with leukemic cells from hCG-PML/RARA transgenic mice (TM) and treated with HF 150 μg/kg/day for 21 days. The leukemic infiltration and the percentage of VEGF+ cells were evaluated by morphology and flow cytometry. The …
引用总数
20162017201820192020202120222023202431344232
学术搜索中的文章